NHS Dudley Health Economy Medicines Formulary
Home > 8 Malignant disease and immunosuppression > 8.1 Cytotoxic drugs > 8.1.5 Other antineoplastic drugs > Everolimus for advanced renal cell carcinoma after previous treatment - NICE TAG TA432

Everolimus for advanced renal cell carcinoma after previous treatment - NICE TAG TA432

1.1 Everolimus is recommended within its marketing authorisation as an option for treating advanced renal cell carcinoma that has progressed during or after treatment with vascular endothelial growth factor targeted therapy, only if the company provides it with the discount agreed in the patient access scheme.

https://www.nice.org.uk/guidance/ta432

Site by Devopa
© Copyright 2021 NHS. All rights reserved.